|
1
|
Jochems C and Schlom J: Tumor-infiltrating
immune cells and prognosis: the potential link between conventional
cancer therapy and immunity. Exp Biol Med (Maywood). 236:567–579.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xiang J, Pan Z, Attah-Poku S, Babiuk L,
Zhang Y and Liu E: Production of hybrid bispecific antibody
recognizing human colorectal carcinoma and CD3 antigen. Mol
Biother. 4:15–23. 1992.PubMed/NCBI
|
|
3
|
Gautherot E, Rouvier E, Daniel L, Loucif
E, Bouhou J, Manetti C, Martin M, Le Doussal JM and Barbet J:
Pretargeted radioimmunotherapy of human colorectal xenografts with
bispecific antibody and 131I-labeled bivalent hapten. J Nucl Med.
41:480–487. 2000.PubMed/NCBI
|
|
4
|
Herrmann I, Baeuerle PA, Friedrich M, Murr
A, Filusch S, Rüttinger D, Majdoub MW, Sharma S, Kufer P, Raum T
and Münz M: Highly efficient elimination of colorectal
tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging
human T cells. PLoS One. 5:e134742010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim DD and Eng C: The promise of mTOR
inhibitors in the treatment of colorectal cancer. Expert Opin
Investig Drugs. 21:1775–1788. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Misale S, Yaeger R, Hobor S, Scala E,
Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M,
Siravegna G, et al: Emergence of KRAS mutations and acquired
resistance to anti-EGFR therapy in colorectal cancer. Nature.
486:532–536. 2012.PubMed/NCBI
|
|
7
|
Tol J and Punt CJ: Monoclonal antibodies
in the treatment of metastatic colorectal cancer: a review. Clin
Ther. 32:437–453. 2010. View Article : Google Scholar
|
|
8
|
Wang ZH, Gao QY and Fang JY: Loss of PTEN
expression as a predictor of resistance to anti-EGFR monoclonal
therapy in metastatic colorectal cancer: evidence from
retrospective studies. Cancer Chemother Pharmacol. 69:1647–1655.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ross JS, Slodkowska EA, Symmans WF,
Pusztai L, Ravdin PM and Hortobagyi GN: The HER-2 receptor and
breast cancer: ten years of targeted anti-HER-2 therapy and
personalized medicine. Oncologist. 14:320–368. 2009.PubMed/NCBI
|
|
10
|
Hillig T, Thode J, Breinholt MF, Franzmann
MB, Pedersen C, Lund F, Mygind H, Sölétormos G and Rudnicki M:
Assessing HER2 amplification by IHC, FISH, and real-time polymerase
chain reaction analysis (real-time PCR) following LCM in
formalin-fixed paraffin embedded tissue from 40 women with ovarian
cancer. APMIS. 120:1000–1007. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Janjigian YY, Werner D, Pauligk C,
Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E,
Tafe LJ, Tang LH, Shah MA and Al-Batran SE: Prognosis of metastatic
gastric and gastroesophageal junction cancer by HER2 status: a
European and USA International collaborative analysis. Ann Oncol.
23:2656–2662. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jørgensen JT and Hersom M: HER2 as a
prognostic marker in gastric cancer-a systematic analysis of data
from the literature. J Cancer. 3:137–144. 2012.PubMed/NCBI
|
|
13
|
Takenaka M, Hanagiri T, Shinohara S,
Kuwata T, Chikaishi Y, Oka S, Shigematsu Y, Nagata Y, Shimokawa H,
Nakagawa M, Uramoto H, So T and Tanaka F: The prognostic
significance of HER2 overexpression in non-small cell lung cancer.
Anticancer Res. 31:4631–4636. 2011.PubMed/NCBI
|
|
14
|
Bergmann F, Moldenhauer G, Herpel E, Gaida
MM, Strobel O, Werner J, Esposito I, Müerköster SS, Schirmacher P
and Kern MA: Expression of L1CAM, COX-2, EGFR, c-KIT and Her2/neu
in anaplastic pancreatic cancer: putative therapeutic targets?
Histopathology. 56:440–448. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Krähn G, Leiter U, Kaskel P, Udart M,
Utikal J, Bezold G and Peter RU: Coexpression patterns of EGFR,
HER2, HER3 and HER4 in non-melanoma skin cancer. Eur J Cancer.
37:251–259. 2001.PubMed/NCBI
|
|
16
|
Schuell B, Gruenberger T, Scheithauer W,
Zielinski Ch and Wrba F: HER 2/neu protein expression in colorectal
cancer. BMC Cancer. 6:1232006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kountourakis P, Pavlakis K, Psyrri A,
Rontogianni D, Xiros N, Patsouris E, Pectasides D and Economopoulos
T: Clinicopathologic significance of EGFR and Her-2/neu in
colorectal adenocarcinomas. Cancer J. 12:229–236. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kavanagh DO, Chambers G, O’Grady L, Barry
KM, Waldron RP, Bennani F, Eustace PW and Tobbia I: Is
overexpression of HER-2 a predictor of prognosis in colorectal
cancer? BMC Cancer. 9:12009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mann M, Sheng H, Shao J, Williams CS,
Pisacane PI, Sliwkowski MX and DuBois RN: Targeting cyclooxygenase
2 and HER-2/neu pathways inhibits colorectal carcinoma growth.
Gastroenterology. 120:1713–1719. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fury MG, Lipton A, Smith KM, Winston CB
and Pfister DG: A phase-I trial of the epidermal growth factor
receptor directed bispecific antibody MDX-447 without and with
recombinant human granulocyte-colony stimulating factor in patients
with advanced solid tumors. Cancer Immunol Immunother. 57:155–163.
2008. View Article : Google Scholar
|
|
21
|
Seimetz D, Lindhofer H and Bokemeyer C:
Development and approval of the trifunctional antibody catumaxomab
(anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer
Treat Rev. 36:458–467. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Clay TM, Custer MC, Sachs J, Hwu P,
Rosenberg SA and Nishimura MI: Efficient transfer of a tumor
antigen-reactive TCR to human peripheral blood lymphocytes confers
anti-tumor reactivity. J Immunol. 163:507–513. 1999.PubMed/NCBI
|
|
23
|
Ma J, Han H, Liu D, Li W, Feng H, Xue X,
Wu X, Niu G, Zhang G, Zhao Y, Liu C, Tao H and Gao B: HER2 as a
promising target for cytotoxicity T cells in human melanoma
therapy. PLoS One. 8:e732612013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fu X, Tao L, Rivera A, Williamson S, Song
XT, Ahmed N and Zhang X: Simple and sensitive method for measuring
tumor-specific T cell cytotoxicity. PLoS One. 5:e118672010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Brown CE, Wright CL, Naranjo A, Vishwanath
RP, Chang WC, Olivares S, Wagner JR, Bruins L, Raubitschek A,
Cooper LJ and Jensen MC: Biophotonic cytotoxicity assay for
high-throughput screening of cytolytic killing. J Immunol Methods.
297:39–52. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Repp R, van Ojik HH, Valerius T,
Groenewegen G, Wieland G, Oetzel C, Stockmeyer B, Becker W,
Eisenhut M, Steininger H, et al: Phase I clinical trial of the
bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in
combination with Filgrastim (G-CSF) for treatment of advanced
breast cancer. Br J Cancer. 89:2234–2243. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lum LG, Rathore R, Cummings F, Colvin GA,
Radie-Keane K, Maizel A, Quesenberry PJ and Elfenbein GJ: Phase
I/II study of treatment of stage IV breast cancer with OKT3 x
trastuzumab-armed activated T cells. Clin Breast Cancer. 4:212–217.
2003.PubMed/NCBI
|
|
28
|
Sheu BC, Lin RH, Lien HC, Ho HN, Hsu SM
and Huang SC: Predominant Th2/Tc2 polarity of tumor-infiltrating
lymphocytes in human cervical cancer. J Immunol. 167:2972–2978.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen ML, Pittet MJ, Gorelik L, Flavell RA,
Weissleder R, von Boehmer H and Khazaie K: Regulatory T cells
suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta
signals in vivo. Proc Natl Acad Sci USA. 102:419–424. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sathaliyawala T, Kubota M, Yudanin N,
Turner D, Camp P, Thome JJ, Bickham KL, Lerner H, Goldstein M,
Sykes M, Kato T and Farber DL: Distribution and
compartmentalization of human circulating and tissue-resident
memory T cell subsets. Immunity. 38:187–197. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Davol PA, Smith JA, Kouttab N, Elfenbein
GJ and Lum LG: Anti-CD3 x anti-HER2 bispecific antibody effectively
redirects armed T cells to inhibit tumor development and growth in
hormone-refractory prostate cancer-bearing severe combined
immunodeficient beige mice. Clin Prostate Cancer. 3:112–121. 2004.
View Article : Google Scholar
|
|
32
|
Karamouzis MV, Konstantinopoulos PA and
Papavassiliou AG: Trastuzumab-mechanism of action and use. N Engl J
Med. 357:16642007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zitron IM, Thakur A, Norkina O, Barger GR,
Lum LG and Mittal S: Targeting and killing of glioblastoma with
activated T cells armed with bispecific antibodies. BMC Cancer.
13:832013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Baban T, Blomberg C, Hoffner E and Yan X:
Anti-HER2 cancer therapy and cardiotoxicity. Curr Pharm Des. June
4–2014.(Epub ahead of print).
|
|
35
|
Wang L, He Y, Zhang G, Ma J, Liu C, He W,
Wang W, Han H, Boruah BM and Gao B: Retargeting T cells for
HER2-positive tumor killing by a bispecific Fv-Fc antibody. PLoS
One. 8:e755892013. View Article : Google Scholar : PubMed/NCBI
|
